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INTRODUCTION 
A large number of active pharmaceutical compounds 
currently under development are poorly water soluble, a 
characteristic which can limit their bioavailability and result 
in formulation challenges1,2. Strategies to address the 
problem encompass the conversion of a crystalline drug 
into an amorphous form to promote its apparent solubility 
and dissolution, thus resulting in a probable increase in 
bioavailability3.  
The production of co-amorphous systems has added value 
to the co-crystallization and amorphization of drugs by 
profiting from the advantages of both strategies to increase 
the apparent solubility of a drug. These systems incorporate 
low molecular mass molecules as co-formers, which are 
mixed with the drug at the molecular level to form one 
single co-amorphous phase1-3. 
The aim of this study is to understand the capability of 
different co-formers (amino, carboxylic and sulfonic acids), 
in the production of co-amorphous systems with olanzapine 
by ball milling, solvent evaporation and quench cooling of 
molten systems. 
MATERIALS AND METHODS 
Olanzapine (OLZ) was obtained from Vega Pharm (China), 
L-tryptophan (TRY) and L-proline (PRO) from 
BioChemica AppliChem (Spain); citric acid (CA), tartaric 
acid (TA), sodium saccharine (SAC) and solvents (ethanol 
and dichloromethane) from Sigma Aldrich (Germany); and 
liquid nitrogen from Air Liquide (Portugal). 
Mixture – Mixtures of OLZ and each of the amino acids 
(TRY and PRO), carboxylic acids (CA and TA) or sulfonic 
acids (SAC) were obtained in a tumble mixer, in molar 
ratios 1:1, 1:2 and 2:1 prior to further processing. 
Milling – 2g of particles in the previous mixture were 
continuously milled in a ball mill (Retsch, PM 100, 
Germany) with 3 mm balls, at 650 rpm, for 24 h. 
Solvent evaporation - 2 g of the previous mixture was 
dissolved in 75 ml dichloromethane. The solvent was 
removed by evaporation at 40°C and reduced pressure; 
residual solvent was removed under vacuum, for 24 h. 
 
Quench cooling – 2g of the mixtures of OLZ and each co-
former were molten and then quench cooled (QC) in 
aluminium beakers. The temperature for each mixture was 
set at 220ºC to assure that all components have melted. 
Each sample was kept in the liquid state for 5 min to ensure 
complete melting with formation of a single liquid phase 
and then quenched cooled with liquid nitrogen. 
 
Solubility assessment 
Water suspensions of each sample were prepared and 
shaken continuously for 12 h. Once equilibrium was 
reached, samples of supernatant were filtered through 
0.22µm PTFE filter and diluted to an appropriate 
concentration to allow quantification of OLZ by UV-Vis 
spectrophotometry (Shimadzu 2000, Japan) analysis (n=3).  
 
Characterization of the samples 
Samples were characterized by differential scanning 
calorimetry (DSC), X-ray powder diffraction (XRPD) and 
Fourier-transform infrared spectroscopy (FTIR). DSC 
studies of OLZ, binary co-amorphous mixtures were 
performed on samples weighing 3-5 mg in hermetic sealed 
crucibles (TA Instruments, Q200, USA). Samples were 
subjected to heating and cooling cycles at a rate of 
10ºC/min, within the range of -40 to 250ºC. 
X-ray diffraction (XRD) patterns were recorded in the 
transmission mode on a diffractometer (Philips Analytical 
PW 3050/60 X’Pert PRO, NL) equipped with a X’Celerator 
detector operating with monochromatized CuKα radiation 
in BraggBrentano geometry. The samples were gently 
consolidated in an aluminium holder and diffractograms 
were obtained by continuous scanning in a 2θ-range at 
40kV and 30 mA from 5–35°.  
Infrared spectra were recorded from all mixtures (FTIR 
spectrophotometer, ALPHA II, Bruker, Germany). Samples 
were placed directly on the crystal and spectra were 
collected over a range of 4000–525 cm-1 (12 scans per 
spectrum). 
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RESULTS AND DISCUSSION 
Results have shown that OLZ could be converted into the 
amorphous state and produce co-amorphous systems. The 
quench cooling technique presented the most promising 
results whereas milling and solvent evaporation do not 
seem to be sufficient to produce co-amorphous systems 
with the blends drug:co-former, containing amino acids and 
carboxylic acids. On the other hand, the sulfonic acid 
(SAC) co-former presented the best results, since a co-
amorphous system could be produced by all the techniques, 
in every molar ratio (Table 1). 
Table 1.  Comparison of the capability of co-amorphization 
using different techniques and co-formers 
 
Figure 1 represents the XRD pattern of OLZ:SAC (1:1) 
showing the typical halo (absence of crystalline peaks) 
suggesting the formation of a co-amorphous system.  
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Figure 1. XPDR of OLZ:SAC (1:1) using solvent evaporation.  
− OLZ:SAC (1:1) − OLZ − SAC  
 
Figure 2 presents the FTIR spectra of OLZ:SAC (1:1) 
which evidenced significant intermolecular interactions 
(hydrogen bonding) between N-H group in OLZ and the 
lactam C=O group in SAC, based on their characteristic 
shifts.  
 
 
 
 
 
 
 
 
 
 
Figure 2. FTIR of OLZ:SAC (1:1) using solvent evaporation. 
Figure 3 shows a set of thermograms for OLZ:SAC (1:1), 
OLZ and SAC and in the first thermogram a formation of a 
single glass transition (Tg=53.04ºC) is observed, suggesting 
the formation of a co-amorphous system. 
 
 
Figure 3. DSC of OLZ:SAC (1:1) using solvent evaporation. 
− OLZ:SAC (1:1) − OLZ − SAC 
As a BCS class II drug, OLZ showed a low solubility in 
demineralized water (40 mg/L). The solubility of co-
amorphous OLZ:SAC was much higher (SE=375x, 
BM=254x and QC=235x) than OLZ alone, or and in 
systems containing the other co-formers (around 30x for 
amino acids and 50x for carboxylic acids). The significant 
solubility improvement observed may increase dissolution 
in vivo and is likely to enhance bioavailability of OLZ.  
CONCLUSION 
The study has shown the possibility of converting OLZ into 
an amorphous entity, in the presence of co-formers, 
significantly promoting solubility.  
Regarding the preparation method quench cooling was 
better than solvent evaporation and milling.  
SAC, a sulfonic acid, was the best co-former probably 
because it is a stronger acid than amino or carboxylic acids, 
but also due to the conjugated ressonance aromatic ring 
promoting the establishment of hydrogen bonds with OLZ 
and amorphization.  
ACKNOWLEDGEMENT 
Fundação para a Ciência e a Tecnologia (FCT) is 
acknowledged for providing financial support to this work 
(PTDC/CTM-BIO/3946/2014). 
REFERENCES 
1. Blaabjerg, L. I.; Lindenberg, E.; Rades, T.; Grohganz, H. 
and Löbmann, K. Influence of preparation pathway on the 
glass forming ability. Int. J. Pharm. 521, 232-238 (2017). 
2. Dengale, S. J.; Grohganz, H.; Rades, T. and Löbmann, K. 
Recent advances in co-amorphous drug formulations. Adv. 
Drug Del. Rev. 100, 116-125 (2016). 
3. Qi, S. and Craig, D. Recent developments in micro- and 
nanofabrication techniques for the preparation of amorphous 
pharmaceutical dosage forms. Adv. Drug Del. Rev. 100, 67-
84 (2016). 
 
 
Mixtures 
(1:1) 
Ball 
Milling 
Quench 
Cooling 
Solvent 
Evaporation 
OLZ:TRY no no no 
OLZ:PRO no yes no 
OLZ:CA no yes no 
OLZ:TA no yes no 
OLZ:SAC yes yes yes 
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